Semi-automated rapid isoelectric focusing of apolipoproteins C from human plasma using PhastSystem(TM) and immunofixation

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 6, 1999, Pages 643-648

  Noll, Bernd ^a,c   Hackler, Rolf ^a   Pelzer, Mirko ^a   Pelzer, Sabine ^a   Nusser, Petra ^a   Maisch, Bernhard ^a   Schaefer, Juergen R ^a   Steinmetz, Armin ^b  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b St Nikolaus Stiftshospital A   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apolipoproteins C I, C II, C III; Coronary heart disease; Immunofixation; Isoelectric focusing; Phastsystem(TM)

Indexed keywords

APOLIPOPROTEIN C;

ANALYTIC METHOD; ARTICLE; BLOOD CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; ISOELECTRIC FOCUSING; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; SILVER STAINING;

ACRYLIC RESINS; APOLIPOPROTEINS C; AUTOANALYSIS; BLOOD PROTEIN ELECTROPHORESIS; CORONARY DISEASE; HUMANS; HYDROGEN-ION CONCENTRATION; ISOELECTRIC FOCUSING; PRECIPITIN TESTS; REPRODUCIBILITY OF RESULTS;

EID: 0032878808     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.100     Document Type: Article

References (31)

1. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985; 26:556-65.
2. La Rosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970; 41:57-62.
3. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 1978; 298:1265-73.
4. Fojo SS, Brewer HB jr. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992; 231:669-77.
5. Paris2: a premature termination mutation in the signal peptide of apo C-II resulting in the familial chylomicronemia syndrome. J Lipid Res 1992; 33:361-7.
6. Olivecrona G, Beisiegel U. Lipid binding of apolipoprotein CII is required for stimulation of lipoprotein lipase activity against apolipoprotein CII-deficient chylomicrons. ArteriosclerThromb Vasc Biol 1997; 17:1545-9.
7. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apolipoprotein of human very low density lipoprotein. Biochem Biophys Res Commun 1972; 46:375-82.
8. Wang C-S, McConathy J, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest 1985; 75:384-90.
9. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart J-C, Wang C-S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 1992; 33:995-1003.
10. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science 1990; 249:790-3.
11. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest 1997; 99:2672-81.
12. Jabs H-U, Assmann G. Characterization of an apolipoprotein C-III mutant by high performance liquid chromatography and time-of-flight secondary ion mass spectrometry. J Chromatogr 1987; 414:323-33.
13. 58→Glu) -Identification of an apolipoprotein-C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 1991; 87:1724-31.
14. Lüttmann S, von Eckardstein A, Wei W, Funke H, Köhler E, Mahley RW, et al. Electrophoretic screening for genetic variation in apolipoprotein C-III: identification of a novel apoC-III variant, apoC-III(Asp45→Asn), in a Turkish patient. J Lipid Res 1994; 35:1431-40.
15. Alpert AJ, Beaudet AL. Apolipoprotein CIII-1 activates lysosomal sphingomyelinase in vitro. J Clin Invest 1981; 68:1592-6.
16. Soutar AK, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM Jr. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin:cholesterol acyltransferase. Biochemistry 1975; 14:3057-64.
17. Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL, Brown MS. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J Biol Chem 1990; 265:22453-9.
18. Swaney JB, Weisgraber KH. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins. J Lipid Res 1994; 35:134-42.
19. Sparks DL, Pritchard PH. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apolipoprotein content. J Lipid Res 1989; 30:1491-8.
20. Poduslo SE, Neal M, Herring K, Shelly J. The apolipoprotein CI A allele as a risk factor for Alzheimer's disease. Neurochem Res 1998; 23:361-7.
21. Esen A. A simple method for casting polyacrylamide gels of varying thickness and size for flat-bed isoelectric focusing. In: Allen RC, Arnaud P, editors. Electrophoresis '81. Advanced methods. Biochemical and clinical applications. Proceedings of the third international conference on electrophoresis. Berlin and New York: Walter de Gruyter, 1981:73-6.
22. Hackler R, Kleine TO. Modification of PhastSystem™ for automated detection of oligoclonal bands in native cerebrospinal fluid by IEF with immunofixation. Lab Med 1991; 15:185-92.
23. Hackler R, Schaefer JR, Motzny S, Brand S, Kleine TO, Kaffarnik H, et al. Rapid determination of apolipoprotein E phenotypes from whole plasma by automated isoelectric focusing using PhastSystem™ and immunofixation. J Lipid Res 1994; 35:153-8.
24. Havel RJ. Postprandial hyperlipidemia and remnant lipoproteins. Curr Opin Lipidol 1994; 5:102-9.
25. Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart JC, et al. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem 1997; 272:31348-54.
26. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38:2173-92.
27. Harake B, Caines PSM, Thibert RJ, Cheung RMC. A simple micromethod for rapid assessment of the distribution of apolipoprotein C isoforms in very-low-density lipoprotein. Clin Biochem 1991; 24:255-60.
28. Sprecher DL, Taam L, Brewer HB Jr. Two-dimensional electrophoresis of human plasma apolipoproteins. Clin Chem 1983; 30:2084-92.
29. Kushwaha RS, Hasan SQ, McGill HC Jr., Getz GS, Dunham RG, Kanda P. Characterization of cholesteryl ester transfer protein inhibitor from plasma of baboons (Papio sp.). J Lipid Res 1993; 34:1285-97.
30. Schaefer JR, Hackler R, Brand S, Schwarz S, Kleine TO, Steinmetz A. Apolipoprotein AI, AII, and AIV isoforms in plasma determined by automated isoelectric focusing with PhastSystem™ and immunofixation. Clin Chem 1995; 41:76-81.
31. Laas T, Olsson I. Ultrathin layer PAGIF: a cost benefit analysis of the focusing distance. In: Allen RC, Arnaud P, editors. Electrophoresis '81. Advanced methods. Biochemical and clinical applications. Proceedings of the third international conference on electrophoresis. Berlin and New York: Walter de Gruyter, 1981:191-203.